Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-13 Sale | 2024-03-15 4:45 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 723 | $28.33 | $20,483 | 77,692 (Direct) | View |
| 2024-03-04 Sale | 2024-03-06 8:13 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 20,646 | $35.49 | $732,727 | 167,941 (Direct) | View |
| 2023-12-14 Sale | 2023-12-18 8:49 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 597 | $20.76 | $12,394 | 77,910 (Direct) | View |
| 2023-09-13 Sale | 2023-09-25 8:31 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,617 | $48.32 | $271,416 | 71,182 (Direct) | View |
| 2023-08-28 Sale | 2023-08-30 7:04 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,745 | $49.99 | $287,191 | 76,799 (Direct) | View |
| 2023-06-21 Sale | 2023-06-23 8:06 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 33,349 | $51.74 | $1,725,390 | 46,627 (Direct) | View |
| 2023-06-13 Sale | 2023-06-15 9:29 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 591 | $55.16 | $32,600 | 79,976 (Direct) | View |
| 2023-01-13 Sale | 2023-01-18 5:30 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,000 | $50.53 | $252,651 | 81,268 (Direct) | View |
| 2022-12-12 Sale | 2022-12-13 8:24 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,000 | $43.23 | $216,137 | 172,647 (Direct) | View |
| 2022-11-10 Sale | 2022-11-14 5:26 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,000 | $39.42 | $197,105 | 72,073 (Direct) | View |
| 2022-10-10 Sale | 2022-10-12 4:59 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,000 | $37.99 | $189,950 | 77,073 (Direct) | View |
| 2022-09-13 Sale | 2022-09-15 7:59 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 40,000 | $27.48 | $1,099,228 | 82,073 (Direct) | View |
| 2021-10-15 Sale | 2021-10-18 4:21 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 12,500 | $21.59 | $269,826 | 120,921 (Direct) | View |
| 2021-09-15 Sale | 2021-09-17 4:05 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 12,500 | $24.69 | $308,605 | 133,421 (Direct) | View |
| 2021-08-16 Sale | 2021-08-17 9:15 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $18.79 | $187,900 | 145,921 (Direct) | View |
| 2021-07-15 Sale | 2021-07-19 4:43 pm | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $20.9 | $209,044 | 155,921 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-04 Exercise | 2024-03-06 8:13 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,000 | $6.36 | 167,941 (Direct) | View |
| 2024-03-04 Exercise | 2024-03-06 8:13 pm | N/A 2029-01-15 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 20,646 | $0 | 167,941 (Direct) | View |
| 2024-03-04 Exercise | 2024-03-06 8:13 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 10,646 | $21.09 | 167,941 (Direct) | View |
| 2023-12-08 Option Award | 2023-12-12 4:26 pm | N/A 2033-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 178,734 | $0 | 224,744 (Direct) | View |
| 2023-09-21 Exercise | 2023-09-25 8:31 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,000 | $6.36 | 71,182 (Direct) | View |
| 2023-09-21 Exercise | 2023-09-25 8:31 pm | N/A 2029-01-15 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,000 | $0 | 71,182 (Direct) | View |
| 2023-08-28 Exercise | 2023-08-30 7:04 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,745 | $6.36 | 76,799 (Direct) | View |
| 2023-08-28 Exercise | 2023-08-30 7:04 pm | N/A 2029-01-15 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 5,745 | $0 | 76,799 (Direct) | View |
| 2023-03-10 Tax Withholding | 2023-03-14 4:20 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 701 | $43.46 | 80,567 (Direct) | View |
| 2022-12-16 Option Award | 2022-12-20 7:52 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 29,073 | $0 | 87,221 (Direct) | View |
| 2022-12-09 Option Award | 2022-12-13 8:24 pm | N/A 2032-12-08 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 105,574 | $0 | 172,647 (Direct) | View |
| 2022-09-09 Option Award | 2022-09-13 9:15 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 58,148 | $0 | 209,295 (Direct) | View |
| 2022-06-30 Option Award | 2022-09-13 9:15 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 1,152 | $8.03 | 209,295 (Direct) | View |
| 2021-12-08 Option Award | 2021-12-10 5:08 pm | N/A 2031-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 87,221 | $0 | 87,221 (Direct) | View |
| 2020-06-30 Option Award | 2020-12-09 8:50 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 1,245 | $17.07 | 242,494 (Direct) | View |
| 2020-12-08 Option Award | 2020-12-09 8:50 pm | N/A 2030-12-07 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 77,580 | $0 | 242,494 (Direct) | View |
| 2019-12-31 Option Award | 2020-01-03 6:16 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 1,025 | $18.87 | 163,669 (Direct) | View |
| 2019-12-13 Option Award | 2019-12-13 9:06 pm | N/A 2029-12-12 | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 85,000 | $0 | 85,000 (Direct) | View |
Ownership | 2019-06-19 6:31 pm | N/A N/A | Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer | 0 | $0 | 274,128 (Direct) | View |